Shujue Lan

Drug Screening Manager

Center for Excellence in Molecular Cell Science, CAS

Short Biography

Dr. Shujue Lan obtained her Ph.D. from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), and was a visiting scholar at Emory University, USA. She is member of the CAS Youth Innovation Promotion Association, Young Editorial Board Member of the Journal of Analytical Testing and Instrumentation, and recipient of the "Outstanding Individual in Shanghai’s Large-Scale Scientific Instrument Sharing Service" award. She has edited High-Throughput Screening Laboratory Manual and is currently compiling the Surface Plasmon Resonance (SPR) Technology Experimental Handbook. Dr. Lan has led several competitive research projects, including grants from the National Natural Science Foundation of China (NSFC) and CAS Instrument Function Development Innovation Programs. Her scholarly work has been published in top-tier journals such as Cell Research, Nat Commun. With extensive expertise in high-throughput screening, she has delivered over 200 customized screening services for CAS institutes, leading universities, tier-3 hospitals, and biotech companies, spanning compound libraries, genome-wide siRNA screens, and ORF library screenings. Her work has contributed to the discovery of lead compounds with clinical trial potential and facilitated the publication of 20+ SCI papers in journals including Science, Cancer Cell, Cell Research.

Presentation Topic: Development and Implementation of High-Throughput Screening Technology Platforms
As the core engine of drug discovery, high-throughput screening (HTS) technology drives the small-molecule drug development process through systematic interaction analysis between large-scale compound libraries and target systems. The Chemical Biology Technology Platform, established at the Chinese Academy of Sciences' Center for Excellence in Molecular Cell Science, has evolved over a decade into a mature drug screening system that integrates target discovery with hit/lead compound identification, accumulating extensive expertise in small-molecule screening.

This presentation will explore critical elements in HTS system development and share mechanism-driven precision screening strategies, aiming to foster discussions on cutting-edge methodologies for small-molecule drug innovation. 
The report is structured into four sections:
• Highlighting the role of academic platforms in pioneering drug discovery.
• Introducing platform architecture
• Development of multidimensional HTS systems:
• Translational HTS campaigns case studies.